
Certain type of coffee linked to crippling eye disease as doctors warn: Stop drinking it, NOW
Chinese researchers say they have found a link between instant coffee and an eye disease that causes blurry or distorted central vision.
They found that those with a preference for instant coffee were up to seven times more likely to develop the disorder than drinkers of other types.
Known as age-related macular degeneration (AMD), it sees the small, central part of the retina wear down, affecting people's ability to read, drive and recognize faces.
Researchers believe the link could be due to the way instant coffee is prepared, which releases a chemical called acrylamide which may enter the bloodstream and damage the retina.
Dr Qi Jia, an ophthalmologist who led the study, warned: 'Instant coffee may increase the risk of age-related macular degeneration, and reducing its intake could help prevent[it].
'People at high risk of age-related macular degeneration should avoid instant coffee.'
People who have a family history of the disease, are overweight, smoke or have high blood pressure are all at higher risk for the condition.
People with blue or green eyes are also at an elevated risk because their eyes contain less pigment, which means they can sustain more damage from sunlight.
But the researchers caution their study was observational and does not prove that instant coffee causes AMD.
Previous studies have actually shown that coffee could reduce the risk of AMD.
A 2023 study involving 67,000 adults linked coffee drinking to a thickening of nerve fiber layers in the eye, helping to protect vision.
However, the new study is one of the few to look at different types of coffee.
The study used data on participants from the UK Biobank and the FinnGen consortium, which tracks genetic data on people in Britain and Finland.
The study didn't strictly look at whether someone drank instant coffee, it used a different methodology involving genes.
There is some evidence that people's genes decide which coffee they prefer, whether they prefer a more bitter or smoother taste and if they can easily tolerate caffeine.
After dividing participants by their genetic predisposition for drinking instant, ground or decaffeinated coffee, they then analyzed the AMD rates.
Results showed those placed in the instant coffee group were 692 percent more likely to be diagnosed with dry age-related macular degeneration — where the macula, in the center of the eye and responsible for central vision, deteriorates over time.
They also said they were 159 percent more likely to suffer from wet age-related macular degeneration — where abnormal blood vessels grow under the macula, causing vision complications.
Decaf drinkers were also found to be 80 percent more likely to suffer from dry AMD, although this difference was not significant.
Participants were only considered to have developed AMD if it appeared after their 50th birthday and was diagnosed by a physician.
AMD is a common condition among older adults, with approximately one in ten Americans aged 50 years or over suffering from the condition.
There is no cure for the condition, but doctors say that starting treatment early can help to slow its progression.
This may include taking supplements like vitamin C, E and zinc, or drugs for wet AMD that can slow the growth of blood vessels in the eyes.
Researchers emphasize that more work is needed to confirm the findings of the study.
Overall, it included 7,600 participants who had dry AMD and 5,900 who had wet AMD.
It was published in the journal Food Science and Nutrition.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
7 hours ago
- Daily Mail
China records more chikungunya cases as it battles 'largest outbreak'
Cases of chikungunya virus continue to rise in China, as the country battles its largest-ever outbreak of the illness. Another 1,387 cases of Chikungunya virus were confirmed last week, Chinese authorities said, with almost all in the southern manufacturing city of Foshan. It takes the tally to more than 10,000 cases overall, with infections also reported in Taiwan and Hong Kong , as well as in Europe and travel-acquired cases in the US. The reported figure for the latest week is, however, below that for the previous seven-day period at 2,892 cases, in a sign that the outbreak could now be slowing. Chinese officials say there have been no cases of severe disease or death reported during the outbreak. The spread of the mosquito-borne disease has triggered restrictions in China not seen since the Covid pandemic, with disinfectant sprayed in streets and patients quarantined in hospitals. Officials have also deployed insecticide-spraying drones, 'cannibal' mosquitoes and killer fish to eliminate any insects that could be carrying the virus. It has also triggered alarm in the US, with CDC officials saying they are 'assessing' the situation and warning Americans to take protective measures, such as wearing insect repellent or long-sleeved clothes if they travel to the area. Experts in the US say the disease is just 'one plane ride' from reaching American shores. China's record-breaking outbreak is in Guangdong province, on the southern coast, with almost all the infections reported in the city of Foshan. In the latest update from the Guangdong Provincial Center for Disease Control and Prevention, revealed by the Yangcheng Evening News, officials reported that of the new cases, 1,212 were in Foshan. Another 103 cases were reported in Guangzhou, the largest city in the province, while 39 cases were reported in Zhanjiang. It was not clear where the other 33 cases were within the province. Officials heralded the figures as the lowest weekly count reported since the peak of the outbreak in the week to July 20 to 26, when they said they recorded 2,940 cases. In a statement to last week, a CDC spokesman said: 'CDC is aware of the reported chikungunya outbreak in Guangdong Province in China and is currently assessing the size and extent of the outbreak.' The agency has already issued a level two warning for the area, advising Americans to take advanced precautions when traveling to the region. On Friday, Hong Kong said it had detected another two cases linked to the outbreak, taking its chikungunya tally to five infections reported this year. One was a 66-year-old woman who was reported to have traveled to Foshan alone from July 24 to August 5 to see family, before returning to Hong Kong. The patient began suffering from fever, rash and joint pain on August 6 and went to the hospital. She has now been discharged. It also reported another suspected case in a healthy 22-year-old woman who was suffering from joint pain and fever. She had recently traveled to Madagascar, Mauritius and Malaysia before returning to the territory, and reported having been bitten by mosquitoes during her trip. Also on Friday, Taiwan reported its first case linked to the outbreak in China, in a woman in her 40s who had recently returned from Foshan and Shenzhen. A day after returning to Taiwan she developed a fever, rash and pain in her limbs. Officials said she was admitted to the hospital. She also reported being bitten by mosquitoes. It is rarely fatal, but can leave people with lifelong complications including joint inflammation and pain that lasts for years. Patients who are very young, elderly or have underlying conditions are most at risk because of their weakened immune systems. There is no treatment for the virus, with doctors instead using over-the-counter painkillers, fluids and rest to ease symptoms. There are two vaccines available.


Reuters
7 hours ago
- Reuters
Sanofi stops supply of high cholesterol drug to China due to limited availability
SHANGHAI, Aug 12 (Reuters) - Sanofi ( opens new tab said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to limited availability. "The surge in demand has led to limited availability in China, and some other countries," Sanofi said in a statement sent to Reuters, adding "at the moment Praluent's supply in China has already stopped." It didn't say when supply would resume. Sanofi said it had "invested to strengthen global production of Praluent, to meet a rising global demand which accelerated sharply over the past two years". The company said clinical experts had found there were other medicines on China's National Reimbursement Drug List that were "safe and appropriate" for patients currently being treated with Praluent and it was working with healthcare providers in China to "ensure a smooth transition for patients". Sanofi is the latest foreign drugmaker to stop supplying popular medications to China. Merck (MRK.N), opens new tab suspended shipments of its blockbuster human papillomavirus vaccine Gardasil to the country in February, citing weak discretionary spending.


Daily Mail
20 hours ago
- Daily Mail
China records more cases of deadly chikungunya virus as country battles 'largest outbreak ever'
Cases of chikungunya virus continue to rise in China, as the country battles its largest-ever outbreak of the illness. Another 1,387 cases of Chikungunya virus were confirmed last week, Chinese authorities said, with almost all in the southern manufacturing city of Foshan. It takes the tally to more than 10,000 cases overall, with infections also reported in Taiwan and Hong Kong, as well as in Europe and travel-acquired cases in the US. The reported figure for the latest week is, however, below that for the previous seven-day period at 2,892 cases, in a sign that the outbreak could now be slowing. Chinese officials say there have been no cases of severe disease or death reported during the outbreak. The spread of the mosquito-borne disease has triggered restrictions in China not seen since the Covid pandemic, with disinfectant sprayed in streets and patients quarantined in hospitals. Officials have also deployed insecticide-spraying drones, 'cannibal' mosquitoes and killer fish to eliminate any insects that could be carrying the virus. It has also triggered alarm in the US, with CDC officials saying they are 'assessing' the situation and warning Americans to take protective measures, such as wearing insect repellent or long-sleeved clothes if they travel to the area. Experts in the US say the disease is just 'one plane ride' from reaching American shores. China's record-breaking outbreak is in Guangdong province, on the southern coast, with almost all the infections reported in the city of Foshan. In the latest update from the Guangdong Provincial Center for Disease Control and Prevention, revealed by the Yangcheng Evening News, officials reported that of the new cases, 1,212 were in Foshan. Another 103 cases were reported in Guangzhou, the largest city in the province, while 39 cases were reported in Zhanjiang. It was not clear where the other 33 cases were within the province. Officials heralded the figures as the lowest weekly count reported since the peak of the outbreak in the week to July 20 to 26, when they said they recorded 2,940 cases. In a statement to last week, a CDC spokesman said: 'CDC is aware of the reported chikungunya outbreak in Guangdong Province in China and is currently assessing the size and extent of the outbreak.' The agency has already issued a level two warning for the area, advising Americans to take advanced precautions when traveling to the region. On Friday, Hong Kong said it had detected another two cases linked to the outbreak, taking its chikungunya tally to five infections reported this year. One was a 66-year-old woman who was reported to have traveled to Foshan alone from July 24 to August 5 to see family, before returning to Hong Kong. The patient began suffering from fever, rash and joint pain on August 6 and went to the hospital. She has now been discharged. It also reported another suspected case in a healthy 22-year-old woman who was suffering from joint pain and fever. She had recently traveled to Madagascar, Mauritius and Malaysia before returning to the territory, and reported having been bitten by mosquitoes during her trip. Also on Friday, Taiwan reported its first case linked to the outbreak in China, in a woman in her 40s who had recently returned from Foshan and Shenzhen. A day after returning to Taiwan she developed a fever, rash and pain in her limbs. Officials said she was admitted to the hospital. She also reported being bitten by mosquitoes. Chikungunya virus can only be spread via the bites of mosquitoes and cannot be passed from human to human. People infected with the virus suffer from a sudden high fever, normally around 103 Fahrenheit (39 Celsius), which happens within two to seven days of infection. They may also suffer from a rash, headache, nausea, fatigue and joint pain. In serious cases, patients may suffer from pain in the hands and feet that is so bad it leaves them struggling to carry out normal activities. It is rarely fatal, but can leave people with lifelong complications including joint inflammation and pain that lasts for years. Patients who are very young, elderly or have underlying conditions are most at risk because of their weakened immune systems. There is no treatment for the virus, with doctors instead using over-the-counter painkillers, fluids and rest to ease symptoms. There are two vaccines available. The US records more than 100 cases of chikungunya virus every year, with almost all normally linked to travelers returning from abroad before testing positive for the virus. Experts are concerned, however, that an infected individual could be bitten by a mosquito, which would then become infected and pass the disease on to others. A total of 45 chikungunya cases have been reported in the US this year, although none have been linked to the outbreak in China.